PhRMA submits additional comments on the FDA 2/24 Rare Disease Day public meeting.
FDA ends its probe of Novartis Zolgensma data manipulation and waives any regulatory action against the company.
Nevadas federal court rules against Amarin in a patent dispute with two generic drug companies over its Vascepa heart drug.
FDA describes its Coronavirus Treatment Acceleration Program to speed the development and deployment of Covid-19 therapies.
FDA accepts a Bristol Myers Squibb and Bluebird Bio BLA for idecabtagene vicleucel, a B-cell maturation antigen-directed chimeric antigen receptor T c...
Coalition for a Prosperous America chief economist Jeff Ferry calls for significant cuts in the countrys reliance on overseas production of drugs and ...
FDA releases its latest batch of Warning Letters that includes Ficosota, Pfizer Healthcare India and Trilogy Laboratories.
Medtronic recalls (Class 1) its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device with Shield Technology because there is a risk...